Health How do I get the COVID-19 medication Paxlovid?
Antivirals could be a pandemic game-changer — and they could be in Canada soon
As a pandemic-weary country confronts another wave of COVID-19 cases with a strained health care system, Health Canada is looking at new products that could offer some relief: antivirals. Two such drugs are making their way through the labyrinthine Health Canada approvals process: Pfizer's Paxlovid and Merck's molnupiravir. These antiviral treatments, which are prescribed by a doctor and administered in pill form, are designed to help the body fight off the SARS-CoV-2 virus, reduce symptoms from an infection and shorten the period of illness.
Paxlovid, an antiviral drug for treatment of COVID-19 made by Pfizer, was approved in Canada on Jan. 17. Health Canada says as of March 31, it has shipped enough doses for 150,000 people to the provinces and territories, allocated on a per capita basis.
But most of the provinces have only given a small percentage of their Paxlovid doses to patients so far, according to emailed responses to CBC News inquiries. In both Ontario and Alberta, for example, only about three per cent of their doses have actually reached patients.
Despite provinces having so many doses on hand that haven't been used, people have told CBC News that the process of trying to get Paxlovid has been fraught with obstacles, ranging fromto a lack of easily .
Health Canada Just Approved At-Home Antiviral Pills For Eligible People With COVID-19
It's Canada's first COVID-19 therapy that can be taken at home.????In a statement on Monday, January 17, the federal agency announced that the prescription-only medication had been authorized to treat adults with mild to moderate COVID-19, who are at risk of progressing to hospitalization or death.
That's a problem, experts say, because to be effective, Paxlovid must be taken within five days of developing symptoms.
"[There are] just so many delays along the way that patients are losing out here on a drug that really can change their prognosis if they're considered high risk," said Dr. Zain Chagla, an infectious diseases specialist at McMaster University.
Here are some basics about Paxlovid, who should take it and where to start if you're trying to get it.
Who is the drug for?
Paxlovid is for adults in the early days of infection who have mild to moderate symptoms of COVID-19 who have a high risk of deteriorating into severe illness and requiring hospitalization. The risk criteria vary by province, but can include being immunocompromised, having serious underlying conditions (such as obesity or diabetes), being older and being unvaccinated.
35 Companies to Produce Generic Version of COVID Pill that Helps Prevent Hospitalization and Death
Paxlovid was shown to be highly effective and was offered emergency use authorization by the FDA in DecemberThirty-five manufacturers around the world have signed on to produce the generic version of Pfizer's COVID-19 antiviral treatment pill Paxlovid.
Eligible patients take Paxlovid at home after testing positive for COVID-19. It is not approved for patients who are already hospitalized with severe or critical COVID-19 symptoms.
How does it work and how do I take it?
is a combination of two antiviral medications: nirmatrelvir and ritonavir. Nirmatrelvir interferes with the proteins the coronavirus needs to multiply and stops it from infecting more cells. Ritonavir slows the breakdown of nirmatrelvir so it stays in the body long enough to do its job.
The medication is in pill form, taken twice a day for five days. The nirmatrelvir and ritonavir pills for each dose are packaged together in a blister pack, so you know how much to take.
Pfizer Begins Trial of COVID Drug Paxlovid in Kids 6 to 17
WEDNESDAY, March 9, 2022 (HealthDay News) -- Pfizer Inc. announced Tuesday that it has launched a Phase 2/3 clinical trial of its COVID antiviral pill known as Paxlovid in children ages 6-17. A news release from the company said the trial will assess the safety and efficacy of the drug in children with COVID symptoms and a confirmed infection who are not hospitalized and are at risk for severe disease. "Since the beginning of the pandemic, more than 11 million children under the age of 18 in the United States alone have tested positive for COVID-19, representing nearly 18% of reported cases and leading to more than 100,000 hospital admissions.
How do I get a prescription?
To get a prescription, you need a positive COVID-19 test.
What you do after that depends on where you live, because the provinces and territories are in charge of distributing drugs.
Gallery: 25 common mental health myths debunked (Espresso)
In most provinces, after you get a positive COVID-19 test, you need to get the prescription from a doctor or nurse practitioner.
If you don't have a primary health-care provider or can't get in touch with them, in some provinces you can consult with a health-care provider through telehealth services (e.g., Service BC in British Columbia, Health Links in Manitoba, Health Line 811 in Saskatchewan, Health Link in Alberta, or Telehealth in Ontario.) Nova Scotia asks patients to fill in an.
A spokesperson for the Yukon government's department of health and social services told CBC North thatof the territory's three hospitals in Whitehorse, Dawson City and Watson Lake.
What about pharmacies?
Quebec is the only jurisdiction in Canada so far that has given pharmacists the authority to prescribe Paxlovid. In the April 1making that announcement, the Quebec government also said that all 1,900 community pharmacies in the province would carry the medication.
COVID-19 antiviral treatments expected to increase on P.E.I.
Paxlovid and other antiviral treatments for COVID-19 are now available on a limited basis and the hope is to expand access as the province gets a greater supply.Other antivirals and treatments are also being used to help treat people with COVID-19.
In most other provinces, once you get a prescription for Paxlovid, you can get it filled at specifically designated community pharmacies. Ontario is an exception, where the medication is only dispensed at COVID-19 assessment centres or hospitals. On Tuesday, Health Minister Christine Elliott said the province plans to add more distribution locations, and that plan may include pharmacies.
Conversations are happening with provincial governments to try to make Paxlovid more accessible through community pharmacies, said Danielle Paes, chief pharmacist officer at the Canadian Pharmacists Association.
"We know that pharmacies are in every jurisdiction," Paes said. "We're able to get it into the communities that need it."
In addition, following Quebec's lead and giving pharmacists prescribing authority for Paxlovid in other provinces would help streamline the process of getting COVID-19 treatment, she said. Pharmacists already administer COVID-19 tests, she said, so a patient could get their test, prescription and medication all in one place.
Precautions need to be taken to reduce the risk of symptomatic patients infecting other people, Paes stressed, noting that Quebec pharmacies are offering delivery of rapid antigen tests to symptomatic patients, and doing consultations over the phone.
COVID-19 drug usage limited by possible risks, supply issues, says N.L. health minster
While hospitalizations and deaths due to COVID-19 are rising in Newfoundland and Labrador, the provincial health minister says there are no plans to expand eligibility for Pfizer's new therapeutic pill yet.John Haggie said supply issues and possible risks mean use of the pills will be limited to those who meet its criteria and have consulted with an infectious disease specialist.
It's important to have "multiple levels of access" to Paxlovid and to simplify the path to getting it, said Chagla, the infectious diseases specialist.
It should be widely available at pharmacies, COVID assessment centres, primary care provider clinics and emergency departments, he said.
I have mild COVID-19 and am at higher risk for hospitalization. Does that mean I should definitely take Paxlovid?
Not necessarily, because thewith a lot of other medications. It's critical you tell your doctor, nurse practitioner or pharmacist what other medications you're on.
They'll help you weigh the risks versus benefits, or decide if you need a dose adjustment.
"Some of the highest-risk people [for severe COVID-19] tend to be people who are taking other medications," said Dr. Emily McDonald, an internal medicine and epidemiology specialist at McGill University Health Centre.
"They may have diabetes or heart disease or cancer. And so the highest-risk people tend to be taking the drugs that are at highest risk of interacting with Paxlovid."
Why are there so many medications that interact with Paxlovid?
For Paxlovid to be effective, it slows how quickly the body metabolizes it. So it can have the same effect on other medications you're taking at the same time.
Health Canada recommends peopleshould not take Paxlovid. They include alfuzosin, which is used to treat high blood pressure; several medications for irregular heartbeat; certain cancer drugs; a few medications used to treat mental health issues, and the herbal product St. John's Wort.
People with liver or kidney disease should talk to their health-care provider before taking Paxlovid, theand say.
Doctors and pharmacists emphasize that the availability of a COVID-19 treatment like Paxlovid is not a replacement for vaccination. Being fully vaccinated still provides the greatest level of protection against severe illness or hospitalization, they say.
New Brunswick to expand eligibility for COVID-19 medication Paxlovid .
New Brunswick plans to expand eligibility for the antiviral drug treatment for COVID-19, Paxlovid, starting Monday. It also plans to give all primary care providers the authority to prescribe it "in an effort to increase uptake," and make it available at all pharmacies, says the Department of Health. "The Department of Health is in the process of expanding its eligibility for Paxlovid which will be communicated in the near future," spokesperson Bruce Macfarlane confirmed in an emailed statement Friday morning.